Industry: Workforce Bill Would ‘Hinder’ Quality of Biosimilar Market

Industry groups are worried that a section of the proposed FDA and NIH Workforce Authorities Modernization Act would exempt biologics from adhering to U.S. Pharmacopeial standards for quality.
Source: Generic Line